The RNA Editing Therapeutics Market was valued at $210.00 Million in 2025 and is projected to reach $2.90 Billion by 2035, growing at a CAGR of 30.0 percent over 2026 to 2035, according to Strategic Revenue Insights. Unmet need in genetic disease is the largest driver, adding 7.5 percentage points to annual growth, because patients with inherited disorders have few treatment options and RNA editing offers a change that is reversible rather than permanent.
Click here for free sample PDF: https://www.strategicrevenueinsights.com/industry/rna-editing-therapeutics-market
RNA Editing Therapeutics Market Key Takeaways
- Market value grows about 13.8x, from $210.00 Million in 2025 to $779.72 Million in 2030 and $2.90 Billion in 2035.
- ADAR-based editing is the largest technology at 48 percent of 2025 value; CRISPR-Cas13 based editing grows fastest at 36.1 percent a year.
- Biopharmaceutical companies hold 68 percent of value and grow at 31.0 percent, paying for platform access, partnerships and clinical programs.
- Genetic disorders are the largest therapeutic area at 34 percent, while liver diseases grow at 33.0 percent and neurological disorders at 32.0 percent.
- North America leads with 52 percent share; Asia Pacific grows fastest at 32.5 percent and passes Europe by 2035.
What Is Driving Growth
Unmet need in genetic disease adds 7.5 percentage points, the largest single effect. Reversible, safer editing adds 6.5 points, because RNA changes do not alter the genome permanently and allow dose adjustment, which matters to regulators and patients. Pharma partnerships and funding add 6.0 points, as large drug makers pay upfront and milestone fees, and delivery technology advances add 5.0 points through better targeting of liver, brain and eye tissue. On the other side, delivery and durability challenges remove 4.5 points and long clinical and regulatory timelines remove 3.5 points, since first approvals are still years away.
Segments, Regions and Key Players
By technology, ADAR-based editing holds 48 percent of 2025 value, oligonucleotide-guided editing 27 percent, CRISPR-Cas13 based editing 17 percent and other technologies 8 percent. By end user, biopharmaceutical companies hold 68 percent, research institutes 20 percent and contract research organizations 12 percent. North America holds 52 percent of value at $109.20 Million and grows to $1.34 Billion at 28.5 percent, Europe holds 22 percent and reaches $661.16 Million, and Asia Pacific holds 20 percent and grows fastest at 32.5 percent to $699.39 Million.
Wave Life Sciences leads with an estimated 16.0 percent share, followed by Korro Bio at 11.0 percent, ProQR Therapeutics at 9.0 percent, Ascidian Therapeutics at 7.0 percent, Shape Therapeutics at 6.5 percent, AIRNA at 5.0 percent and Rznomics at 3.5 percent. Roche, Ionis Pharmaceuticals and Arrowhead Pharmaceuticals add large-company strength in partnerships, oligonucleotide chemistry and targeted delivery. The five largest companies hold about 50 percent of revenue.
Frequently Asked Questions
How big is the RNA Editing Therapeutics Market?
The market was valued at $210.00 Million in 2025 and is projected to reach $2.90 Billion by 2035, a 30.0 percent CAGR from 2026 to 2035.
How is RNA editing different from gene editing?
RNA editing changes RNA sequences in the body instead of DNA, so the edit lives in RNA and fades unless the dose is repeated, which makes it reversible and allows dose adjustment.
Which region grows fastest?
Asia Pacific grows fastest at 32.5 percent a year and reaches $699.39 Million by 2035, while North America remains the largest region at 52 percent of 2025 value.
About Strategic Revenue Insights Inc.
Strategic Revenue Insights Inc., a subsidiary of SRI Consulting Group Ltd headquartered in London, provides syndicated market research reports, consulting and strategic insights. Contact: sales@strategicrevenueinsights.com | www.strategicrevenueinsights.com